Ascentage Pharma Group International

As of June 30, 2026, Ascentage Pharma Group International carries a market capitalization of 12.40B, placing it among publicly traded companies globally. Its enterprise value stands at 12.64B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Ascentage Pharma Group International's next confirmed earnings release is scheduled for March 31, 2027.

As of June 30, 2026, Ascentage Pharma Group International has 373.56M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Ascentage Pharma Group International maintains a current ratio of 1.22, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Ascentage Pharma Group International's stock has declined approximately 57.84% over the past 52 weeks. The 50-day moving average sits at 31.81, while the 200-day moving average is 40.12.

As of June 30, 2026, Ascentage Pharma Group International holds 2.19B in cash and equivalents against 2.42B in total debt, resulting in a net debt position of 202.56M. Total book value stands at 643.06M, with working capital of 473.59M providing operational flexibility.